Amneal Pharmaceuticals (AMRX) Misses Q4 EPS by 3c ; Offers Guidance

Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q4 EPS of $0.12, $0.03 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $731 million versus the consensus estimate of $703.74 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2025 EPS of $0.65-$0.70, versus the consensus of $0.71. Amneal Pharmaceuticals sees FY2025 revenue of $3-3.1 billion, versus the consensus of $2.92 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• JPMorgan Starts TIME dotCom Berhad (TDC:MK) at Overweight
• UBS Downgrades Grand Korea Leisure (114090:KS) to Neutral
• Deutsche Bank Downgrades Synaptics (SYNA) to Hold